This decision would depend on several factors; the patient's frailty status, disease spread, molecular signatures, and response thus far. If she continues to respond well to the platinum couplet, my approach would involve adding bevacizumab if it hasn't been administered yet. I might also consider a...

The question posed describes a relatively common scenario. She has platinum-sensitive disease and to date, has had only a partial response to front-line therapy. Her overall prognosis is worse compared with patients who are surgically resectable, regardless of the number of neoadjuvant chemotherapy ...